Genos offers $399 CLIA Certified Whole Exome Sequencing to Consumer.

[Genos]

Genos offers $499 Whole Exome
Sequencing with CLIA certificate to Consumers.

Visit https://www.genosresearch.com


OWN YOUR DNA
Purchase a DNA kit and discover your exome, which is the most revealing part of your genome.

- High-quality whole exome sequencing
- Enriched data visualization tools to browse your genomic data
- Personalized sessions with board-certified genetic counselors at preferred rates
- Educational content, including interactive tutorials

LEAD EXPLORATION

Browse inspiring and cutting edge research being conducted on the Genos platform. For studies of interest, choose to share your data with distinguished researchers. Studies will begin in Fall 2016.

RECEIVE COMPENSATION

You will be fairly compensated for sharing data that’s rightly yours when researchers accept your request to participate in a study.

Join Genos

Genomeweb Coverage on Genos: https://www.genomeweb.com/molecular-...-explore-share

[ECO]

I would love to know the technical details of the assay:


--sequencing config (PE, SE, 75,100,150,???)
--Enrichment technology used
--Regions targeted
--Depth of sequencing, ie how many on-target reads are you generating (please don't say 50M loci like your website).
--insert size

--deliverables to customer (FASTQ? BAM? VCF? all?)

[ECO]

I found "75x on-target coverage" but that doesn't speak to uniformity or gaps etc....

[Genos]

Consumers can have their whole exomes sequenced at Genos.
Consumers OWN their data!

Researchers can also work with Genos to recruit participants for studies and Genos handles the entire participant recruitment process, from finding participants, registration, and sequencing through data delivery, and liberates researchers from tedious admin work.

1. Our sequencing is conducted in a CLIA certified Lab.
2. We are using Agilent SureSelect commercial enrichment chip, ~50mb targeted regions.
3. We use Illumina HiSeq Platform, PE 100.
4. We require 75x on-target depth (after reads are adapter masked, mapped, duplicates removed.), which is defined as on-target yield / target size. The raw throughput (raw data off the sequencer) may have about 130x-140x or higher.
5. We also have very high requirements on uniformity, e.g. very high percentage requirements on 1x and 20x loci. We will communicate the numbers individually for now. The uniformity requirements is higher than most of research projects published.
6. We require samples have to match BOTH 75x and uniformity requirements.
7. Deliverable to consumers: VCF (with SNP and indels and no-calls (regions not covered by sequencing or not confident to call))
8. Deliverables to researchers: (if the researcher sets up a study and consumers contribute and consent to give their data): VCF, self reported phenotypic data.

Originally Posted by ECO

I would love to know the technical details of the assay:


--sequencing config (PE, SE, 75,100,150,???)
--Enrichment technology used
--Regions targeted
--Depth of sequencing, ie how many on-target reads are you generating (please don't say 50M loci like your website).
--insert size

--deliverables to customer (FASTQ? BAM? VCF? all?)

[bruce01]

Owning data legally requires ultimate control and exclusive rights of use. Does Genos relinquish rights of use and all control of the data?

[Genos]

Thanks for asking this question because our principle of data ownership truly differentiates us from other companies.

One of our core principles is that Genos does not claim any ownership of a user’s genetic data in any capacity and that participant's data remains the property of the user, NOT Genos.

Genos will only share the data with researchers with whom the user has specifically consented to share data. A user is also free to download and export the data and port their genomes to other content providers and may ask Genos to delete the account and remove the data from our platform at any time. More details are available in our Terms of Service.

Originally Posted by bruce01

Owning data legally requires ultimate control and exclusive rights of use. Does Genos relinquish rights of use and all control of the data?

[Genos]

We are going to ASHG 2016, Vancouver, Oct 18-21.
It's our first presence in conferences.
Visit us at Booth 432.

[Genos]

TechCruch Report on us:
Genetics startup Genos wants to pay you for your DNA data

[Trof]

You are saying Illumina HiSeq Platform, but on your current info page for users, the sequencing step is described as using a ligase and probes. That looks more like cPAL than Illumina SBS approach.

Did you change the sequencing technology in the meantime, or is the info page (Sequencing Journey) somehow outdated?